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What's new? 
 The burden of diabetes and its treatment may cause psychosocial stress. 
 Good metabolic control improves psychosocial well-being. 
 Identifying people early in the disease course through screening and introducing long-
term intensive treatment does not cause psychosocial harm. 
 Clinicians and public health systems implementing early detection and intensive 
treatment protocols for type 2 diabetes do not need to worry that these may have a 
long-term adverse impact on peoples’ psychosocial well-being. 
 
 
Abstract 
Aims To present the longer-term impact of multifactorial treatment of type 2 diabetes on self-
reported health status, diabetes-specific quality of life, and diabetes treatment satisfaction at 
10-year follow up of the ADDITION-Europe trial. 
Methods The ADDITION-Europe trial enrolled 3057 individuals with screen-detected type 2 
diabetes from four centres [Denmark, the UK (Cambridge and Leicester) and the 
Netherlands], between 2001 and 2006. Participants were randomized at general practice level 
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to intensive treatment or to routine care . The trial ended in 2009 and a 10-year follow-up was 
performed at the end of 2014. We measured self-reported health status (36-item Short-Form 
Health Survey and EQ-5D), diabetes-specific quality of life (Audit of Diabetes-Dependent 
Quality of Life questionnaire), and diabetes treatment satisfaction (Diabetes Treatment 
Satisfaction Questionnaire) at different time points during the study period. A mixed-effects 
model was applied to estimate the effect of intensive treatment (intention-to-treat analyses) on 
patient-reported outcome measures for each centre. Centre-specific estimates were pooled 
using a fixed effects meta-analysis. 
Results There was no difference in patient-reported outcome measures between the routine 
care and intensive treatment arms in this 10-year follow-up study [EQ-5D: –0.01 (95% CI –
0.03, 0.01); Physical Composite Score (36-item Short-Form Health Survey): –0.27 (95% CI –
1.11, 0.57), Audit of Diabetes-Dependent Quality of Life questionnaire: –0.01 (95% CI –0.11, 
0.10); and Diabetes Treatment Satisfaction Questionnaire: –0.20 (95% CI –0.70, 0.29)].  
Conclusions Intensive, multifactorial treatment of individuals with screen-detected type 2 
diabetes did not affect self-reported health status, diabetes-specific quality of life, or diabetes 
treatment satisfaction at 10-year follow-up compared to routine care.  
 
Introduction 
A diagnosis of type 2 diabetes is an impactful life event as this disease is associated with 
micro- and macrovascular complications and reduced self-reported quality of life [1]. The 
burden of both disease and treatment may lead to psychosocial stress and low levels of 
treatment satisfaction [2], while better glycaemic control has been shown to improve 
psychosocial outcomes [3,4]. Furthermore, intensive treatment of cardiovascular risk factors 
in people with longstanding type 2 diabetes and microalbuminuria has markedly reduced the 
incidence and progression of complications [5–7], which may also improve longer-term 
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psychological outcomes.  
The balance between potential harm and benefit of a diabetes diagnosis and lifelong 
multifactorial treatment is particularly important for individuals with screen-detected type 2 
diabetes, who have few or no symptoms of the disease but are still encouraged to initiate 
medical treatment and lifestyle changes following diagnosis. Patient-reported outcome 
measures (PROMs) are found to be good indicators of self-reported health and self-perceived 
treatment satisfaction and good predictors of mortality, and are used in many studies to assess 
health status [8,9]. 
The Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen Detected 
Diabetes in Primary Care (ADDITION-Europe), a pragmatic, cluster-randomized controlled 
trial in general practice in Denmark, England and the Netherlands, found a 17% non-
significant relative risk reduction in cardiovascular morbidity and mortality at 5-year follow-
up [3] and a 13% non-significant reduction after 10 years of follow-up [10], comparing 
routine care to the intensive treatment. The ADDITION-Europe trial found no differences in 
self-reported health status, diabetes-specific quality of life, and diabetes treatment satisfaction 
between the intensive treatment and the routine care  group after 5 years [11]. This suggests 
that multifactorial, intensive treatment of the intervention group does not influence PROMs in 
people with screen-detected type 2 diabetes. Previous findings support this result. The UK 
Prospective Diabetes Study (UKPDS) reported no impact of intensified treatment on self-
reported health in people with a recent clinical diabetes diagnosis, although self-reported 
health  was affected by the complications of the disease [4]. Likewise, the ACCORD trial 
found no clinically significant difference in PROMs between treatment groups after 4 years of 
follow-up [12]. No previous studies have examined the association between multifactorial 
diabetes treatment and PROMs in people with screen-detected type 2 diabetes over a longer-
term follow-up. A longer follow-up period provides greater opportunity to detect differences 
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that may arise only after several years of living with the disease and its treatment. 
Furthermore, analyses based on more than two time points enable the quantification of the 
magnitude of change in either group. We therefore evaluated the effect of multifactorial 
diabetes treatment on self-reported health status [36-item Short-Form Health Survey (SF-36) 
and the EQ-5D questionnaire], diabetes-specific quality of life [Audit of Diabetes-Dependent 
Quality of Life (ADDQoL) questionnaire], and diabetes treatment satisfaction [Diabetes 
Treatment Satisfaction Questionnaire (DTSQ)] after 10 years of follow-up among people with 
screen-detected diabetes in the ADDITION-Europe trial.  
 
Participants and methods 
The ADDITION-Europe trial consisted of a screening study and a cluster-randomized 
controlled trial which was performed in four centres in Denmark, the UK (Cambridge and 
Leicester), and the Netherlands. The design of the ADDITION-Europe trial has been described 
in detail elsewhere [13–16]. In brief, 343 general practices were randomized to provide 
intensive multifactorial treatment or routine care to people with newly diagnosed,  type 2 
diabetes detected by screening. The randomization took place before the start of the screening 
programme. The diagnosis of type 2 diabetes was based on the WHO 1998 criteria [17]. 
Individuals were excluded if they had a life expectancy shorter than 12 months, were 
housebound, pregnant or lactating, or had psychological or psychiatric illness that might 
invalidate informed consent. A total of 3057 individuals with type 2 diabetes were identified 
by screening and included in the ADDITION-Europe trial between 2001 and 2006. The 
intervention ran for 5 years until 31 December 2009 [18]. No attempts were made to maintain 
differences in treatment between study groups after the end of the intervention. Ten-year 
follow-up (5-year post-intervention) ended on 31 December 2014 [mean (SD) follow-up 9.6 
(3.0) years] [10].  
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Intervention 
General practices in the intensive treatment group were instructed to deliver a multifactorial, 
intensified target-driven treatment. The multifactorial treatment differed slightly between the 
centres [15,18] . The treatment targets for the intensive treatment group were: HbA1c <53 
mmol/mol (7.0%); blood pressure ≤135/85 mmHg; cholesterol < 5 mmol/l, if there was no 
history of coronary heart disease, and <4.5 mmol/l in case of previous cardiovascular disease; 
and prescription of aspirin if treated with anti-hypertensive medication. The intervention 
consisted of both pharmacological treatment and promotion of healthy lifestyle. Treatment 
targets, and the means to achieve the targets, have been described in detail elsewhere [10,18]. 
The routine care group were advised to follow the national guidelines for type 2 diabetes 
treatment in the respective countries. 
Measurements and outcomes 
Clinical and anthropometric measures at baseline and 5 years were collected at clinical 
examinations in each centre following standard operating procedures. At 10-year follow-up 
data were retrieved from general practice records and national registers. Information on death 
prior to 10-year follow-up was collected from national registers and a composite outcome of 
first cardiovascular event was assessed by an independent adjudication committee in each 
centre based on the participant’s medical records and national registers. Measures are 
described in detail elsewhere [10]. 
The PROMs were obtained from self-administrated questionnaires and collected at different 
time points in each centre. The questionnaires included self-reported health status, diabetes 
treatment satisfaction and quality of life, and covered both generic and diabetes-specific 
measures. 
The EQ-5D consists of a classification system (EQ-5D Profile) and a visual analogue scale 
(EQ-VAS) [19,20]. The EQ-5D profile covers five domains of health, namely: mobility; self-
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care; usual activities; pain/discomfort; and anxiety/depression. Each domain has three levels 
of functioning: level 1, no problems; level 2, some problems; and level 3, severe problems. 
Responses are summarized and recoded as a number between –1 and +1, where 0 means 
death, optimal health is 1 and negative numbers indicate health states rated as worse than 
death. The EQ-VAS is a graded, vertical line, anchored at 0 (worst imaginable health state) 
and 100 (best imaginable health state). Participants were requested to mark the point on the 
EQ-VAS that best indicated their current health state. 
The SF-36 generates a profile of scores on eight dimensions of health [21] . The Physical 
Composite Score (PCS) and Mental Composite Score (MCS) are calculated based on eight 
dimensions and range likewise from 0 to 100, with the latter indicating the best heath state. 
DDQoL examines the impact of diabetes on specific aspects of well-being of study 
participants, and is designed for clinical and research use [22]. Whereas generic measures of 
health status (e.g. SF-36) may be strongly affected by non-diabetes-related comorbidity, 
ADDQoL scores reflect the impact of diabetes-related complications only. The scores range 
from –3 (a great deal better) to 1 (worse) and are generated by rating of the importance of the 
item from 3 (very important) to 0 (not at all important). Scores are calculated by multiplying 
the unweighted responses by the importance rating. The total score is the mean of all the 
weighted ratings and ranges from –9 (the maximum negative impact of diabetes) to 3 (the 
maximum positive impact of diabetes). 
The DTSQ is used to measure patient satisfaction with diabetes treatment [23]. It consists of a 
six-item scale assessing treatment satisfaction. The treatment satisfaction score ranges from 0 
(very dissatisfied) to 36 (very satisfied). 
Statistics 
The trial analysis was performed using an intention-to-treat approach, which compared 
participants according to the randomized treatment allocation, regardless of the intensity of 
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treatment received. The analyses considered the randomization effect over the entire 10-year 
follow-up period, even though the active intervention stopped after the 5-year trial period. 
The population’s PROM characteristics are presented by randomization group, separately for 
each centre. For continuous variables, means and standard deviations were used, unless the 
variable had a highly skewed distribution, in which case, medians (25th and 75th percentiles) 
are presented. PROMs were collected at different time points at the centres (in Denmark at 0, 
5 and 10 years, in Cambridge at 0, 1, 5 and 10 years, and in Leicester and the Netherlands at 0 
and 5 years, while no 10-year PROMs data were collected in these latter two centres). For 
each outcome, the number of missing values is reported. 
For PROMs, participants with missing data at the 5-year and the 10-year follow-up are likely 
to be the individuals who experienced the most serious illness or, alternatively, individuals 
who do not consider their symptomless diabetes as a serious disease. These missing data can 
consequently not be assumed to be ‘missing completely at random’, so simply excluding these 
participants could have led to selection bias. We therefore performed multiple imputation 
before analysing data by including clinical variables from baseline and follow-up 
examinations that could explain the observed pattern of missing data. This approach assumes 
that data are ‘missing at random’, i.e. that the missingness pattern is dependent on observed 
variables. We used the MICE framework [24] to carry out a 60-fold multiple imputation and 
subsequently summarized results according to Rubin’s rules [25]. All further analyses were 
performed based on these 60 estimates. Individuals who died before the 5-year follow-up or 
before the 10-year follow-up were excluded from the analyses at those respective time points 
as they did not contribute to the respective analyses. 
Analyses were performed using mixed-effects models with time since baseline as the 
underlying time scale. This allowed us to accommodate the different measurement time 
sequences per scale and per centre and make optimal use of all available data. Models had a 
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fixed time-independent term of 0 at baseline, to reflect the fact that by virtue of the 
randomized design, baseline values are assumed to be equal in both study arms. The models 
yield estimates for the time-dependent differences in the respective outcomes by treatment 
arm. We use the mixed-effect model to estimate the differences for each centre, when 
comparing the intensive treatment with routine care. Estimates were given as unstandardized 
β-coefficients and afterwards pooled across the centres using a fixed-effects meta-analysis 
with inverse variance weighting; that is, with a fixed centre effect and common intervention 
effect and weighting for the different numbers of observations per centre. This method was 
used because, in the context of a randomized controlled trial, the estimand can reasonably be 
assumed to be the same across centres. 
The I2 statistic, representing the proportion of variability between centres due to 
heterogeneity, was calculated. A sensitivity analysis was performed repeating all analytical 
steps with a complete-case approach (non-imputed outcome data). For all outcomes, the 
standard errors were adjusted to account for intra-cluster correlation, with the general 
practices as clusters. The intervention effect was reported together with a 95% CI. All 
analyses were performed using STATA 15. 
 
 
Ethics 
 
The ADDITION-Europe trial was approved by local ethics committees in each centre. All 
participants provided written informed consent before inclusion in the original trial. 
 
Results 
A total of 3057 individuals participated in the ADDITION-Europe trial; 1678 in the intensive 
group and 1379 in the routine care group. The flow of participants is plotted in Fig. 1. 
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Baseline demographics and other participant characteristics were similar between the 
intervention and control groups (Table 1).  All the available PROMs included in the multiple 
imputation analyses are shown in Table 2. The table contains time point, numbers, number of 
missing values and means with standard deviation by centre and randomization group. 
The centre-specific and overall estimated differences between randomized groups for each 
examined PROM are plotted in Figs 2 and 3. There was no statistically significant difference 
between the intensive treatment group and the routine care  group in PROMs, either by centre 
or in the overall meta-analysed estimates [EQ-5D: estimated difference –0.01 (95% CI –0.03, 
0.01); EQ-VAS: estimated difference –0.46 (95% CI –1.80, 0.87); PCS: estimated difference 
–0.77 (95% CI –1.11, 0.57); MCS: estimated difference –0.11 (95% CI –0.87, 0.65); 
DDQoL: estimated difference –0.01 (95% CI –0.11, 0.10);  and DTSQ: estimated difference 
–0.20 (95% CI –0.70, 0.29)]. Our meta-analysis models showed no evidence of heterogeneity 
(P values for heterogeneity >0.05). Sensitivity analyses showed slightly higher mean values 
for the non-imputed outcomes compared to the imputed, however, there was no material 
difference in the estimated between-group differences when comparing imputed and non-
imputed outcomes (data not shown). 
Discussion 
Overall, we found no difference in self-reported health status, diabetes-specific quality of life, 
and diabetes treatment satisfaction between the intensive and routine care group in the 10-year 
follow-up of the multicentre ADDITION-Europe trial. This suggests that receiving intensive, 
multifactorial diabetes treatment after being diagnosed with type 2 diabetes following 
screening did not influence health status and diabetes-specific quality of life after 10 years. 
The PROM results throughout the ADDITION-Europe trial should be seen in light of the 
concurrent differences in treatment intensity and in the primary outcome. At the 5-year 
follow-up, the ADDITION-Europe trial found a lower composite cardiovascular disease event 
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risk in the intensive arm, albeit not at a statistically significant level, while the treatment 
burden in this arm was higher [18]. In that same time window, the PROM results were similar 
between the two treatment arms [11]. 
At the 10-year follow-up the intensive treatment arm still showed a non-statistically 
significant lower primary event risk compared to the routine care arm [10], but the differences 
in treatment burden had largely disappeared and both trial arms had good glycaemic control. 
In this light, we might have expected the PROMs at 10 years to favour the intensive treatment 
group more than at 5 years, but this was not the case, suggesting that PROMs are not directly 
driven by medical treatment burden, but perhaps rather by the overall burden of 
comorbidities.   
 strength of the present study is that we had a long follow-up in a large diabetes treatment 
trial among individuals with screen-detected type 2 diabetes from three different European 
countries and in different settings, including both urban and rural. This long follow-up period 
and large sample size enabled us to confidently exclude the presence of potential harmful 
effects of even relatively modest magnitude. Furthermore, our repeated measures of patient-
reported outcomes allowed us to analyse how intensive multifactorial treatment after screen-
detected diabetes diagnosis affects PROMs when comparing the intensive to routine care 
group. Using mixed-effect models allowed us not to exclude participants with either missing 
baseline or follow-up values. We used validated generic and diabetes-specific questionnaire 
scales. Parallel consideration of different PROMs has been found to be important in the 
overall evaluation of diabetes treatment regimens, as these self-reported scales measure 
different aspects of the influence of disease and treatment on daily life [26] .  
The present study also has some limitations. Not all centres collected 10-year follow-up 
questionnaires, hence it was not possible to calculate change estimates for all four centres. In 
the 10-year follow-up of the trial we had some missing outcome data, which can only be 
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considered to be ‘missing not at random’ as one might reasonably expect that the individuals 
who did not complete the questionnaires were those who were more seriously ill. Although 
this process was arguably non-differential, affecting the intensive treatment and routine care 
arms in equal measure, it was important to attempt to limit its impact on the study results. We 
performed multiple imputation using state-of-the-art methods, which take all available 
determinants of missing observations into account, but are based on the assumption of 
‘missing at random’. Although this procedure cannot fully remove the impact of selection, we 
judged it preferable to a complete-case analysis, which would have accentuated the bias 
caused by selection. Sensitivity analyses showed no material difference in the results based on 
imputed and non-imputed (complete-case) analytical approaches. This suggests that the 
imputation procedure has improved the power of our study, without introducing further bias. 
Sensitivity analyses excluding the centres Leicester and the Netherlands found similar results, 
suggesting that, although data were not available from all centres at all time points, the 
estimates are likely to be robust.  
As ADDITION is a randomized controlled trial with similar inclusion criteria and the same 
intervention in all the four centres, the study populations, intervention and outcome measures 
are sufficiently homogenous across units to justify the prespecified meta-analysis. Indeed the 
primary endpoint of the trial (composite cardiovascular event) exhibited no heterogeneity 
between centres. The meta-analysis performed in this study showed no evidence of 
heterogeneity, confirming that our approach of using a fixed-effects meta-analysis is 
appropriate. Our study population was identified by screening and thereby earlier in the 
disease trajectory than clinically diagnosed people. While some participants had indications of 
complications at baseline, the prevalence of complications at diagnosis is clearly lower than in 
other diabetes trials, which recruited people with an established diagnosis. Participants in our 
study had a mean baseline HbA1c of 53 mmol/mol (7%), whereas other diabetes study 
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populations had mean levels in the range of 58.5–67.2 mmol/mol (7.5–8.3%) [5,27,28]. While 
8% of our participants had cardiovascular disease before diagnosis, other studies report 
prevalence of cardiovascular disease in the range of 22%–35%. The generic PROM levels 
after 10 years of follow-up of the ADDITION-EUROPE trial were lower compared to the 
general population in the same age range, which suggests the ADDITION population has a 
higher disease or treatment burden than the general population. For example, the mean EQ-
5D score in the general Danish population (60–69 years) has been reported to be 0.88 for men 
and 0.84 for women [29]. In ADDITION-Denmark the respective values were 0.84 (men) and 
0.78 (women; intensive treatment). For EQ-VAS, the UK score for the general population 
(65–74 years) was 77.3 [30] compared to 72.4 (intensive treatment) in ADDITION-
Cambridge. However, our results also indicate that ADDITION participants experienced a 
lower burden of disease compared to other diabetes populations. This indicates that results 
from the ADDITION-Europe cannot directly be extrapolated to healthcare systems in 
countries with lower performance. 
In the ACCORD trial [12], participants who were on average 2 years older than our participants, 
with a mean diabetes duration of 9–10 years, had a mean PCS of 37.4 compared to 41.2 in 
ADDITION-Cambridge. The PANORAMA study [34], a  multinational study of people with 
type 2 diabetes with a mean age of 65.9 years and a mean diabetes duration of 8.9 years, found 
a relatively negative impact of diabetes on quality of life (ADDQoL –1.69) compared to the 
ADDITION trial (Denmark: –0.80, Cambridge: –1.05). The study reported a diabetes treatment 
satisfaction score (DTSQ: 29.8) comparable to the ADDITION trial (Denmark: 30.2, 
Cambridge: 29.5) [12,26]. Our results with regard to the impact of intensive treatment on self-
reported health status, diabetes-specific quality of life, and diabetes treatment satisfaction are 
in line with findings from other studies. The UKPDS found that intensive treatment of blood 
glucose did not affect self-reported health status [4]. The ACCORD trial found a small but not 
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clinically relevant difference in the physical component score of the SF-36 between the 
intensive glycaemic control and the comparison group in a 4-year follow-up [12]. In this 10-
year follow-up of individuals identified with type 2 diabetes by screening, we found that levels 
of self-reported health status were higher than in clinically detected diabetes populations with 
longer diabetes duration. We found no association between intensive treatment and self-
reported health status or quality of life compared to routine care. These results indicate that 
intensive, multifactorial treatment of individuals with type 2 diabetes did not adversely affect 
patient-reported outcome measures.  
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FIGURE 1  Flow of practices and participants in follow-up of ADDITION-Europe. 
FIGURE 2 Estimated differences in EQ-5D and the its visual analogue scale component (EQ-
VAS) between the routine care (RC) and intensive treatment (IT) groups at 10 years of 
follow-up. Estimated differences are unstandardized β coefficients between RC and IT. 
FIGURE 3 Estimated differences in physical composite score (PCS), mental composite score 
(MCS; both from the SF-36), Audit of Diabetes Quality of Life (ADDQoL) and Diabetes 
Treatment Satisfaction Questionnaire (DTSQ) between the routine care and intensive 
treatment groups at 10-year of follow-up of the ADDITION-Europe trial. Estimated 
differences are unstandardized β-coefficients between routine care (RC) and intensive 
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treatment (IT).  SF-36, 36-item Short Form Health Survey. 
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Table 1 Baseline characteristics of participants in ADDITION-Europe 
 
Routine care 
 N = 1379 
Intensive treatment 
 N = 1678 
Baseline characteristics 
 
Value 
Total 
with data 
available 
Value 
Total 
with data 
available 
Men, n (%) 
 
790 (57.3) 1379  981 (58.5) 1678  
Mean (SD) age at diagnosis, years  60.2 (6.8) 1379  60.3 (6.9) 1678  
White ethnicity, n (%) 1246 (93.4) 1334  1539 (95.8) 1607  
Employed, n (%) 425 (42.0) 1013  482 (40.3) 1197  
History of myocardial infarction, n (%) 
 
79 (6.1) 1286  109 (6.8) 1593  
History of stroke, n (%) 
 
24 (1.9) 1270  45 (2.9) 1558  
Current smokers, n (%) 375 (27.8) 1347  444 (26.9) 1649  
Median (IQR) units of alcohol /week 4.0 (1 to 13) 1183  4.0 (1 to 13) 1492  
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Mean (SD) BMI, kg/m2 
 
31.6 (5.6) 1342  31.6 (5.6) 1615  
Mean (SD) weight, kg 
 
90.3 (17.6) 1344  90.9 (17.5) 1615  
Mean (SD) HbA1c, mmol/mol 
 
53.5 (16.7) 1298  53.3 (17.3) 1591  
Mean (SD) systolic blood pressure, mmHg  
 
149.8 (21.3) 1346  148.5 (22.1) 1617  
Mean (SD) diastolic blood pressure, mmHg 86.5 (11.3) 1346  86.1 (11.1) 1618  
Mean (SD) total cholesterol, mmol/l  
 
5.6 (1.2) 1300  5.5 (1.1) 1593  
IQR, interquartile range. 
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Table 2 Earliest available patient-reported outcome measures, number of observations and time point, ADDITION-Europe 
PROMs Denmark 
N = 1533 
Cambridge 
N = 867 
Leicester 
N = 159 
 The Netherlands  
N = 498 
IT RC IT RC IT RC IT RC 
T n/ 
missing 
Mean (SD) n/ 
missing 
Mean (SD) n/ 
missing 
Mean (SD) n/ 
missing 
Mean (SD) n/ 
missin
g 
Mean (SD) n/ 
missing 
Mean (SD)  n/ 
missing 
Mean (SD)  n/ 
missing 
Mean (SD) 
                  
  EQ-5D 0 861/49 0.84 (0.2) 597/26 0.85 (0.2) 443/9 0.82 (0.2) 409/6 0.81 (0.2) 53/8 0.73 (0.3) 68/30 0.82 (0.2) 233/22 0.81 (0.2) 215/28 0.82 (0.2) 
 5 696/142 0.85 (0.2) 463/115 0.84 (0.2) 351/77 0.81 (0.2) 312/67 0.83 (0.2) 60/1 0.75 (0.3) 85/10 0.79 (0.2) 176/70 0.86 (0.2) 144/85 0.82 (0.3) 
 10 520/194 0.86 (0.2) 358/156 0.85 (0.2) 202/184 0.79 (0.2) 174/174 0.77 (0.3)  -  -  -  - 
  EQ-
VAS 
0 824/86 76.0 (16.4) 574/49 76.1 (16.2)  -  -  -  - 184/71 75.1 (17.3) 180/63 76.4 (16.2) 
 5 692/176 76.8 (16.9) 462/116 76.4 (18.5) 355/73 76.1 (18.0) 316/63 78.4 (16.4) 60/1 78.3 (16.3) 88/7 74.8 (18.4) 175/71 76.5 (13.7) 144/85 75.3 (15.6) 
 10 517/197 77.1 (17.4) 370/116 76.6 (16.8) 201/184 75.8 (17.0) 169/175 75.0 (17.4)  -  -  -  - 
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  PCS 
 
0 
 
845/65 47.0 (9.8) 593/30 47.1 (9.5) 358/94 45.5 (11.3) 351/64 45.0 (10.9) 
 
 
 -  -  -  - 
 5 666/172 46.7 (10.0) 428/150 46.7 (9.6) 350/78 43.9 (11.6) 310/69 44.5 (11.3) 59/2 44.3 (11.4) 84/11 43.3 (10.5) 177/69 46.8 (10.4) 144/85 47.0 (10.5) 
 10 465/249 46.4 336/148 45.9 (10.0) 189/196 41.6 (11.9) 175/169 40.8 (11.5)  -  -  -  - 
  MCS 0 845/65 54.1 (9.1) 593/30 54.0 (9.3) 358/94 52.8 (9.8)* 351/64 52.7 (9.2)*  -  -  -  - 
 5 666/172 55.3 (9.1) 428/150 54.9 (8.5) 350/78 53.4 (10.6) 310/69 54.6 (8.4) 59/2 50.9 (10.1) 84/11 52.2 (9.9) 177/69 54.3 (8.2) 144/85 53.7 (7.4) 
 10 465/249 54.3 (9.2) 336/148 53.6 (9.2) 189/196 53.7 (9.3) 175/169 53.7 (9.3)  -  -  -  - 
ADDQoL 5 553/285 -0.73 (1.2) 348/230 -0.69 (1.1) 315/113 -0.84 (1.3) 271/108 –0.87 (1.3) 50/11 -1.20 (1.8) 76/19 -2.39 (2.5) 169/77 -0.55 (0.9) 135/94 –0.55 (0.9) 
 10 503/211 -0.70 (1.0) 356/158 -0.74 (1.2) 201/184 -0.93 (1.3) 176/168 –0.92 (1.1)  -  -  -  - 
DTSQ 5 649/189 30.9 (6.2) 405/173  30.1 (6.7) 344/84 31.5 (4.9) 305 /74 31.2 (5.4) 60/1 33.0 (3.8) 85/10 29.1 (7.3) 174/72 31.2 (5.6) 140/89 31.0 (5.6) 
 10 499/215 31.4 (5.8) 345/169 31.1 (6.3) 201/184 31.1 (5.5) 178/166 31.3 (5.1)  -  -  -  - 
ADDQoL, Audit of Diabetes-Dependent Quality of Life; DTSQ, Diabetes Treatment Satisfaction Questionnaire; EQ-5D, Euroqol 5 Dimensions; EQ-VAS, visual analogue 
scale of EQ-5D; IT, intensive treatment; PCS, Physical Composite Score (SF-36); MCS, Mental Composite Score (SF-36); RC, routine care; SF-36, 36-item Short-Form 
Health Survey.  
T = time since inclusion: 0, 1 or 5 years of follow-up. *PCS and MCS from Cambridge were measured at 1 year. 
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Figure 1.   Flow of practices and participants in follow-up of ADDITION-Europe 
 
176 practices allocated to screening and 
routine care 
167 practices allocated to screening and 
intensive treatment 
 
343 practices randomized 
1678 participants identified by screening 
in 161 practices 
 
1379 participants identified by screening 
in 157 practices 
654 participants with complete PROM 
data 
473 participants with incomplete PROM 
data at 10-year follow-up 
 
 
511 participants with complete PROM 
data 
334 participants with incomplete PROM 
data at 10-year follow-up 
 
19 practices excluded: 
 
  12 withdrew before screening 
  7 found no eligible participants 
6 practices excluded: 
 
  5 withdrew before screening 
  1 found no eligible participants 
 
142 participants died before  
10-year follow-up 
283 participants from the 
Netherlands and Leicester were not 
assigned to the 10-year PROM 
questionnaire 
7 participants withdrew consent 
5 participants lost to follow-up 
 
 
126 participants died before  
10-year follow-up 
302 participants from the 
Netherlands and Leicester were not 
assigned to the 10-year PROM 
questionnaire 
5 participants withdrew consent 
9 partici ants lost to follow-up 
 
92 participants died before  
5-year follow up 
104 participants died before  
5-year follow-up 
1087 participants with complete PROM 
data, 
487 participants with incomplete PROM 
data at 5-year follow-up 
at five-year follow-up 
 
830 participants with complete PROM 
data, 
457 participants with incomplete PROM 
data at 5-year follow-up 
at five-year follow-up 
A
cc
ep
te
d 
A
rt
ic
le
 
 
Figure 2. Estimated differences in EQ-5D and EQ-VASbetween the RC and IT groups at 10 years of follow-
up, ADDITION-Europe 
EQ-5D: Euroqol 5 Dimensions – EQ-VAS: Visual Analogue Scale  
IT: Intensive treatment - RC: Routine care 
Estimated differences is unstandardised beta-coefficients between RC and IT 
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Figure 3. Estimated differences in PCS, MCS, ADDQoL and DTSQ between the RC and IT groups at ten-
year of follow-up, ADDITION-Europe 
SF36: 36-item Short Form Health Survey – PCS: physical composite scale from SF36 – MCS: mental 
composite scale from SF36 ADDQoL: Audit of Diabetes Quality of Life, DTSQ: Diabetes Treatment 
Satisfaction Questionnaire 
IT: Intensive treatment, RC: Routine care 
Estimated differences is unstandardised beta-coefficients between RC and IT 
 
 
